Compare RNW & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNW | AAPG |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United Kingdom | China |
| Employees | 4336 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.6B |
| IPO Year | N/A | N/A |
| Metric | RNW | AAPG |
|---|---|---|
| Price | $5.46 | $23.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $7.00 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 689.5K | 1.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.97 | $368.64 |
| P/E Ratio | $14.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.05 | $17.56 |
| 52 Week High | $8.24 | $48.45 |
| Indicator | RNW | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 47.36 | 33.48 |
| Support Level | $5.27 | N/A |
| Resistance Level | $5.63 | $26.55 |
| Average True Range (ATR) | 0.12 | 0.92 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 58.33 | 2.18 |
ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.